Patients with thin lips hyaluronic acid filler, lip enhancement
Conditions
Interventions
Patients were treated with hyaluronic acid filler for lip enhancement. Then they were instructed to follow up at 1, 3 and 6 months after treatment.
Experimental Device
Sponsors
Thanya Techapichetvanich
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. aged 18-60 years 2. Patients with very thin to thin lips
Exclusion criteria
Exclusion criteria: 1. Participants with permanent facial implants below the subnasal region (e.g., polymethyl methacrylate [PMMA], silicone, or polytetrafluoroethylene [PTFE]). 2. Participants who have previously undergone autologous fat grafting or calcium hydroxyapatite (CaHA) injections below the subnasal region. 3. Participants who have received semi-permanent dermal fillers (e.g., poly-L-lactic acid [PLLA]) below the subnasal region within 6 months prior to enrolment, or temporary dermal fillers within 3 months prior to enrolment. 4. Participants who have received botulinum toxin injections within 6 months prior to enrolment or who plan to undergo botulinum toxin treatment during the study period. 5. Participants who have undergone skin resurfacing procedures, including laser therapy, radiofrequency, ultrasound-based treatments, or chemical peels, within 6 months prior to enrolment or who plan to undergo such procedures during the study period. 6. Participants who have received mesotherapy within 3 months prior to enrolment or who plan to undergo mesotherapy during the study period. 7. Participants with a history of hyaluronic acid dermal filler injection to the lips prior to enrolment. 8. Participants who have undergone thread lifting within 6 months prior to enrolment. 9. Participants who have undergone or are scheduled to undergo orthodontic treatment or dental procedures involving the oral region (e.g., tooth extraction) within 1 month prior to enrolment or during the study period. 10. Participants currently receiving anticoagulant therapy. 11. Participants who have taken non-steroidal anti-inflammatory drugs (NSAIDs), traditional herbal medicines, or other herbal products known to affect blood coagulation within 10 days prior to treatment. 12. Participants with active infection, inflammation, scars, or other lesions involving the lips or perioral region that may interfere with efficacy assessment. 13. Participants with a history of porphyria. 14. Participants with tattoos, piercings, or scars involving the lips or perioral region that may interfere with study assessments. 15. Participants with a known hypersensitivity or allergy to hyaluronic acid or its components. 16. Participants with a history of cardiac conduction abnormalities, hepatic disease, renal disease, or autoimmune disorders. 17. Participants who are pregnant, planning to become pregnant, or breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lip Fullness 1, 3 and 6 months after treatment Lip Fullness Scale | — |
Secondary
| Measure | Time frame |
|---|---|
| Physician improvement scale 1, 3 and 6 months after treatment GAIS,Patient improvement scale 1, 3 and 6 months after treatment GAIS,Average Wrinkle and Texture 1, 3 and 6 months after treatment Antera3D,lip volume 1, 3 and 6 months after treatment Vectra H2, Quantificare,lip volume 1, 3 and 6 months after treatment Vectra H2, Quantificare,Pain Score immediate after treatment Visual analog scale | — |
Countries
Thailand
Contacts
Public ContactThanya Techapichetvanich
Faculty of Medicine Siriraj Hospital, Mahidol University
Outcome results
None listed